
Index

- Achondroplasia (dwarfism), 7, 30, 31
 Ad hoc studies, epidemiologic, 14, 103, 104, 107
 Adenine (A), 23, 24, 27, 64, 66
 Adenosine deaminase deficiency, 105
 Agarose gel electrophoresis, 59, 60, 61, 63, 68
 Agency for Toxic Substances and Disease Registry (ATSDR), 18-19
 Agent Orange, 18
 Alanine, 27
 ALARA principle, 114
 Alkylating agents, 93-94
 Alleles, 27, 44, 77, 82
 Alpha-globin chain, 47
 Alpha-thalassemia, 29
 American Society of Human Genetics, 19
 Ames test, 15, 118
 Amino acids, 9, 25-27, 29, 44, 46, 47, 49, 57, 58, 78; *see also specific amino acids*
 Amniocentesis, 41
 Animals, mutation studies in, 3-5, 6-7, 19, 48, 78, 81-87, 91-100, 117-118
 Aniridia, 7
 Antibodies, in somatic mutation studies, 77-78
 Apert's syndrome, 31
 Arginine, 27
 Asparagine, 27
 Aspartic acid, 27
 Atomic Bomb Casualty Commission, 48
 Atomic bomb survivors, effects of radiation on, 9-10, 32, 48-50, 77, 86, 106, 108
 Atomic Energy Act, 114
 Atomic Energy Commission (AEC), 82, 114
 Autoradiographic assay, in somatic mutation studies, 74-75
 Autoradiography, 56, 59, 61, 64, 65, 68, 74-75
 Autosomes, 27, 38, 42, 44, 46, 49

 Bacteria, 81, 91, 92, 94, 116, 117, 118
 Benzo[a]pyrene, 97
 Beta-globin chain, 47, 77
 Biochemical analyses, 37, 44-48, 49-50, 51, 52
 Biologic extrapolation, *see* Extrapolation, qualitative
 Biological effects of ionizing radiation, 113
 Biological samples, banking of, 17-18
 Blood cells, somatic mutation studies on, 73-78
 Blood proteins
 detection of variants in, 44-48, 49-50
 electrophoretic analysis of, 8-9, 10, 37, 44-46, 50, 51, 83
 molecular analysis of, 46-48
 see also, Enzymes; Hemoglobin proteins

 Cancer, 3, 7, 9, 15, 31-32, 38, 50, 73, 77, 104-105, 108-109, 117
 Cancer registries, 105, 109
 Case-control studies, in epidemiologic testing, 107
 Cells, *see* Blood cells; Chorionic villi cells; Germ cells; Red blood cells; Somatic cells; Stem cells; TG⁺ cells; White blood cells
 Centers for Disease Control, 18
 Chemicals
 denaturing, 12, 59, 61
 effects on DNA, 23, 59, 81
 effects on germinal mutations, 7, 9
 effects on heritable mutations, 6-7
 effects on somatic mutations, 7, 74-78
 in extrapolation models, 93-97, 100
 as mutagenic agents, 6-7, 9, 32, 48, 91-97, 106
 "standards" for, 17
 Chemotherapy, 108
 Children, genetic diseases in, 7-8, 30-32, 37, 38-40, 47-48, 49/ 50, 109, 110
 Chorionic villi cells, 41
 Chromosomes
 abnormal at birth, 41-43
 banding methods, 8, 28, 41, 42, 43, 50
 biochemical analyses of, 49-50
 cytogenetic analysis of, 37, 40-43, 49, 52, 55, 98
 DNA and, 23-25, 27-28, 41, 43
 health effects of abnormal, 40-43, 49
 mutations in, 5, 6, 8, 9, 13, 29-30, 31, 32, 40-43, 49, 51, 68, 82, 92, 95
 numerical abnormalities, 8, 29-30, 31, 41, 49, 116
 pulsed field gel electrophoresis and, 68
 staining methods, 8, 28, 41, 42, 43, 50
 structural abnormalities, 8, 29, 31, 41, 49
 studies in mice, 82
 surveillance of abnormal, 105
 translation of, 30, 82
 Chronic hemolytic anemia, 46, 47
 Clonal assay, in somatic mutation studies, 75
 Cloning, 58-59, 60, 64-65, 75
 Codons, 6, 25-27, 29
 Cohort studies, in epidemiologic testing, 107, 109
 Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA), 3, 15, 114
 Congenital hypothyroidism, 105
 Consumer Product Safety Act, 114
 Consumer Product Safety Commission, 114
 Cyanosis, 47
 Cyclophosphamide, 97
 Cysteine, 27

- Cytogenetic analysis, of chromosome abnormalities, 37, 40-43, 49, 52, 55, 98
- Cytosine (C), 23, 24, 27, 64, 66
- Cytotoxic drugs, 108
- Deoxyribonucleic acid (DNA)
 chromosomes and, 23-25, 27-28, 41, 43
 current methods for studying, 6-10
 denaturing of, 11-12, 59-64
 double helix, 24, 25, 27
 double-stranded, 12-13, 23, 59-68
 EPA guidelines and, 116
 extrapolation studies and, 91-100
 Federal expenditures on research, 121-122
 function and organization of, 23-28
 genetic nature of, 3, 4, 5-6
 genomic, 6, 11, 55, 57-68
 heteroduplexes, 12, 55, 61, 62, 63, 64-65, 67
 homoduplexes, 61, 63, 67
 hybridization, 66-67
 nontranscribed, 45
 nucleotide chains in, 23-25
 organizational hierarchy of, 6
 replication of, 23-25, 74
 sequencing, 23-25, 55, 57-58, 60, 61-64, 66-67, 104
 single-stranded, 12-13, 59-68
 structure of, 23-25, 81
 use of new technologies in examining, 10-14, 17, 55-69, 74-76
- Department of Defense, 114
- Department of Energy (DOE), 16, 17, 19, 55, 114, 122
- Department of Transportation, 114
- Diabetes, 3
- Dioxin, 106
- Disease registries, 104-106, 107
- Diseases
 dominant, 44
 environmental factors in, 31
 genetic, 3, 5, 7-8, 9, 30-33, 37, 38-40, 42, 44-45, 47-48, 49, 50, 93, 94, 103-110, 108-109, 110, 115
 "multifactorial," 31
 recessive, 44
 see *also* Sentinel phenotypes and **specific diseases**
- DNA-RNA heteroduplex analysis, 12, 64-65
- Dominant lethal test, 81-82
- Dominant mutation tests, 83
- Dose-response relationships, in quantitative extrapolation studies, 97-99
- Down syndrome, 3, 8, 30, 31, 42
- Drosophila, 48, 81, 82, 96, 116, 117
- Duchenne muscular dystrophy, 3, 30
- Electrophoresis, 8-9, 10, 11-12, 13, 37, 44-46, 49, 50, 51, 55, 68, 83, 84
 see also Gel electrophoresis *and specific types of gel electrophoresis*
- Embryos, in rodent tests, 81-82
- Endonucleases, restriction, use in detecting mutations, 11
- Environmental Protection Agency (EPA), 15, 16, 19, 114, 115, 116, 117
- Enzymes
 biochemical analyses of, 49-50
 HPRT, 74
 kinetic studies of, deficiency variants, 44, 45-46
 quantitative studies of deficiency variants, 45-46, 83, 84
 restriction, 11, 13, 58-64, 66, 67, 68, 75
 RNaseA, 12
 role in protein synthesis, 25-27
 somatic mutation studies on, 73
- Epidemiologic studies, 9-10, 14, 18, 49, 103-110
- Epstein-Barr virus, 104
- Escherichia coli**, 58, 60
- Ethylene dibromide (EDB), 115, 117
- Ethylene oxide (EtO), 115, 117
- Ethylnitrosourea (ENU), in quantitative extrapolation studies, 97, 98-99
- Eukaryotes, 92, 94, 95, 116
- Exposure registries, 106, 107
- Extrapolation
 aims of, 91-92
 from animal to human data, **86-87**
 defined, 14-15
 limits of, 99-100
 qualitative, 15, 91, 94-97, 99-100
 quantitative, 15, 91, 97-100, 115, 117
 theoretical models for, 15, 93-94
- Federal Food, Drug, and Cosmetics Act, 114
- Federal Insecticide, Fungicide, and Rodenticide Act, 115
- Federal Radiation Council (FRC), 113, 114
- Fetuses, chromosome abnormalities in, 40, 42, 82
- Fluorochrome, 77
- Food and Drug Administration (FDA), 19, 114
- Fruit flies, see *Drosophila*
- Fungi, 92
- Galactosemia, 105
- Gamma radiation, 97
- Gel electrophoresis, 11-12, 13, 55, 56, 58, 59, 65
 see *also* Agarose gel electrophoresis; One-dimensional denaturing gradient gel electrophoresis; Pulsed field gel electrophoresis; Two-dimensional denaturing

- gradient gel electrophoresis; Two-dimensional polyacrylamide gel electrophoresis
- Genes
 dominant, 27, 44, 51
 globin, 29, 46, 47-48, 55
hprt, 55, 74-76
 mutations in, 5, 6-7, 29, 38-40, 42-43, 44, 47-48, 50, 51, 55, 57-68, 74-76, 92, 95
 recessive, 27, 44
- Genomes and genomic sequencing, 6, 11, 57-58, 66-67, 68
- Germ cells, 6, 7, 9, 13, 27, 30, 31, 37, 38, 39, 48, 49, 80-84, 91-100, 108, 115-116, 117; see also Germinal mutations
- Germinal mutations
 in cells, 7
 defined, 6
 electrophoretic studies on, 51
 new, 37-38
 radiation-induced, 9-10, 48-49
 relationship to somatic mutations, 73
 see *also* Mutations
- Glossary of Acronyms and Terms, vii-xii
- Glutamic acid, 26, 27, 29
- Glutamine, 27
- Glycine, 27
- Glycophorin A, 76-77
- Glycophorin assay, in somatic mutation studies, 76-77
- Guanine (G), 23, 24, 27, 64, 66
- "Guidelines for Mutagenicity Risk Assessment," 116
- Health effects
 of chromosome abnormalities, 40-43
 of mutations, 4, 30-32, 108-109
 see *also* Children; Diseases; Humans; Infants
- Heart disease, 3, 25, 32
- Hemoglobin A (HbA), 46
- Hemoglobin assays, in somatic mutation studies, 77-78
- Hemoglobin C, 77
- Hemoglobin M (HbM), molecular analysis of, 44, 46-48, 51
- Hemoglobin S, 77
- Hemoglobins, unstable, molecular analysis of, 44, 46-48, 51
- Hemophilia, 3
- Heritable mutations
 chemicals and, 6-7, 9, 32, 48, 91-97
 defined, 6
 detection and measurement of, 11-13
 epidemiologic studies in, 9-10, 14, 18, 49, 103-110
 estimating effects in humans from animal data, 86-87
 extrapolation of data to predict risk in humans, 91-100
 factors that influence induced rates in mice, 84-86
 health effects of, 30-32, 108-109
 induced by chemicals, 6-7
 kinds and rates of, in humans, 32-33, 37-52
 laboratory studies on, 81-87
 new technologies and, 3, 10-14, 55-69
 rodent tests for, 81-84
 spontaneous, studies in humans, 7-10
 see *also* Mutations
- Heritable translocation tests (HTTs), 82, 94-96, 98
- Heteroduplexes, 12, 55, 61, 62, 63, 64-65, 67
- Heterozygotes, 44, 45, 77, 82
- Histidine, 27, 47
- Histidinemia, 105
- Hodgkin's disease, 108
- Homocystinuria, 105
- Homoduplexes, 61, 63, 67
- Homologous sequences, 64
- Homozygotes, 44, 82
hprt, 55, 74-76
- Humans
 animal studies and, 84-87
 epidemiologic studies in, 9-10, 14, 18, 49, 103-110
 Federal expenditures on mutation research in, 121-122
 frequencies of *hprt* T-lymphocytes in, 76
 health effects of mutations in, 30-32, 108-109
 kinds and effects of mutations in, 4, 5-6, 29-32
 kinds and rates of heritable mutations in, 32-33, 37-52
 mutagenic risk predictions by extrapolation, 91-100
 mutation studies in, 3-4, 7-14, 19, 44-52, 55-69, 73-78
 new technologies for detecting mutations in, 10-14, 55-69, 73-78
 persistence of new mutations in, 32-33, 37
 sentinel phenotypes in 7-8, 37, 38-40, 45, 50, 51, 52, 55, 105, 106, 109
 spontaneous mutation rates in, 32-33, 51
 see *also* Children; Diseases; Infants
- Huntington disease, 31
- Hypoxanthineguanine phosphoribosyl transferase (HPRT), 74
- Infants, genetic diseases in, 7-8, 30-32, 37, 38-40, 42, 44-45, 49, 50, 109
- Insects, 91, 92, 116

- International Commission for Protection Against Environmental Mutagens and Carcinogens (ICPEMC), 55
- International Commission on Radiological Protection (ICRP), 113, 114
- International dioxin registry, 106
- Isoleucine, 27
- Karyotypes, 28, 41, 42
- Kinetic studies, of enzyme deficiency variants, 45-46
- Laboratory studies, of heritable mutation rates, 81-87; see *also* Animals
- Lambda (virus), 59, 60
- Leucine, 27
- Leukemia, 9, 32, 109
- Lysine, 26, 27
- Maple syrup urine disease, 105
- Marfan's syndrome, 31, 109
- Measurement techniques, validation of, 104
- Messenger RNA (mRNA), 25, 26
- Methemoglobinemia, 47
- Methemoglobinemic cyanosis, 46
- Methionine, 27
- Methyl isocyanate, 106
- Mice
 - effects of radiation on, 82-86, 97
 - in extrapolation tests, 93, 96
 - factors affecting mutations in, 84-86
 - heritable mutation tests in, 82-84
 - mutation effects in females, 85-86
 - mutation effects in males, 84-85
 - spermatogonial studies in, 84-85, 97-98
 - unscheduled DNA synthesis in spermatids of, 97-98
- Mine Safety and Health Administration (MSHA), 114
- Monitoring, in epidemiologic testing, 14, 103-104, 106, 107
- Mortality and morbidity, 31, 41, 49, 82
- Mouse spot test, 96
- Mutagenicity assays, 91-100; see *also* Mutations *and specific tests for mutagenicity*
- Mutants, in somatic mutation studies, 74-78; see *also* Mutations
- Mutations
 - animal studies, 3-5, 6-7, 19, 48, 78, 81-87, 117-118
 - at birth, 41
 - in chromosomes, 5, 6, 7, 8, 9, 13, 29-30, 31, 32, 40-43, 49, 51, 68, 82, 92
 - at conception, 41
 - current methods for studying, 6-10, 37-52
 - dominant, 32, 38, 44
 - environmental factors in, 3, 4, 37, 73, 96, 106, 108-109
 - Federal expenditures on research, 15, 18, 117, 121-122
 - in genes, 5, 6-7, 29, 38-40, 42-43, 44, 47-48, 50, 51, 55, 57-68, 74-76, 92, 95
 - genetic inheritance and, 23-33
 - germinal, see Germinal mutations
 - health effects of, 4, 30-32, 108-109
 - heritable, see Heritable mutations
 - human studies, 3-4, 7-14, 19, 44-52, 55-69, 73-78, 103-110
 - kinds of, and effects in humans, 4, 5-6, 29-32, 55
 - new, persistence of in humans, 32-33, 37, 41
 - new technologies for detecting in humans, 10-19, 55-69
 - options for research on, 16-19
 - in proteins, 3, 8-9, 25-27, 29, 44-48, 49, 56-57
 - recessive, 32, 33
 - regulatory considerations, 15, 17, 113-118
 - somatic, see Somatic mutations
 - spontaneous, 5, 7, 32-33, 51, 83
 - test methods for research in, 14-16
 - X-linked (sex-linked), 32, 37, 38
- National Cancer Institute, 104
- National Center for Toxicological Research, 19
- National Council on Radiation Protection and Measurements (NCRP), 113, 114
- National Environmental Protection Act of 1970, 114
- National Institutes of Health (NIH), 122
- National Research Council (NRC), 32-33
- National Toxicology Program (NTP), 19
- Neuroblastoma, 109
- Nuclear Regulatory Commission (NRC), 106, 108, 114
- Nucleotides and nucleotide sequencing, 5-6, 8, 11, 12, 23-25, 29, 44, 46, 47, 57-58, 59, 61, 66, 68, 93
- Occupational Safety and Health Act, 114, 115
- Occupational Safety and Health Administration, 114, 115
- Office of Technology Assessment (OTA), 4, 15, 121
- One-dimensional denaturing gradient gel electrophoresis, 55, 59-61, 63
- Oocytes, in mice, 85-86
- Osteogenesis imperfecta, 30

- Parallelogram, as extrapolation model, 93, 97, 117
 Peripheral blood lymphocytes (PBLs), 97
 PFGE, see Pulsed field gel electrophoresis
 Phenotypic data
 limitations of, 40, 45
 mutation rates estimated from, 39-40
 surveillance of, 38-40
 see also Sentinel phenotypes
 Phenylalanine, 26, 27
 Phenylketonuria (PKU), 45, 105
 Polyacrylamide, use in protein separation, 5.5, 56-57
 Polymorphisms, 58-59, 64
 Polypeptide chain, 26, 37, 46; see also Proteins
 Prokaryotes, 94, 95
 Proline, 27
 Proteins
 biochemical analysis of, 37, 44-48, 49-50, 51, 52
 DNA and, 23-27, 45, 46, 50, 57
 mutations in, 3, 8-9, 25-27, 29, 44-48, 49, 56-57
 one-dimensional separation of, 8-9, 44-45, 49, 56
 synthesis of, 25-27
 variant, mutation studies on, 8-9, 44-50, 55, 56-57, 73-74
 two-dimensional separation of, 9, 56-57
 see also Amino acids; Blood proteins; Enzymes; Hemoglobins, Nucleotides and nucleotide sequencing
 Public Health Service, 18
 Pulsed field gel electrophoresis (PFGE), 13, 55, 68

 Qualitative studies, 15, 91, 94-97, 99-100
 Quantitative studies, 15, 45-46, 55, 91, 97-100, 115, 117

 Radiation
 effects on atomic bomb survivors, 9-10, 32, 48-50, 77, 86, 106, 108
 effects on DNA, 23
 effects on fruit flies, 82
 effects on human germ cells, 9
 effects on mice, 82-86, 97
 effects on pregnant women, 9
 effects on U.S. citizens, 86-87, 106
 in extrapolation studies, 97-100
 in Marshall Islands populations test, 50
 in somatic mutation studies, 74
 mutagenic effects of, 73
 U.S. Government efforts to protect humans from, 113-114
 Radiation Effects Research Foundation, 16, 48, 104
 Radioactive thymidine, 74
 Red blood cells, somatic mutation studies on, 73, 76-78

 Regulatory considerations
 definition of germ-cell mutagen, 115-117
 mutagenicity and carcinogenicity, 117-118
 new methods for measuring mutation rates, 118
 protection against agents other than radiation, 114
 quantitative extrapolation, 117
 radiation protection, 113-114
 role of U.S. Government, 15, 17, 113-118
 Research and public policy, use of new technologies in, 14-16
 Restriction fragment length polymorphisms (RFLPs), 55, 58-59, 60
 Retinoblastoma, 7, 31, 109
 Ribonuclease A (RNaseA), 64, 65
 Ribonuclease cleavage of mismatches in RNA/DNA heteroduplexes, 12, 55, 64-65
 Ribonucleic acid (RNA)
 heteroduplexes, 55, 64-65
 role in protein synthesis, 26, 45
 Risk assessment, EPA guidelines for, 116
 RNA, transcribed, 45
 RNA/DNA heteroduplexes, ribonuclease cleavage of mismatches in, 12, 55, 64-65
 Rodents, heritable mutation tests in, 81-84

 Salmonella, 118
 Sentinel phenotypes, 7-8, 37, 38-40, 45, 50, 51, 52, 55, 105, 106, 109; see also Phenotypic data
 Serine, 27
 Sickle-cell anemia, 105
 Sister-chromatid exchange (SCE), 99, 116
 6-TG, use in somatic mutation studies, 74-75
 Somatic cells, 7, 13-14, 27, 31-32, 73, 91-100, 115, 116, 117; see *also* Somatic mutations
 Somatic mutations
 defined, 6
 detection and measurement of, 4, 13-14
 effects of, 31-32
 new methods for measuring in humans, 73-78
 see *also* Mutations
 Specific locus tests (SLTs), 50, 82-83, 85, 94-96, 97-98, 116
 Spermatogonial studies in mice, 84-85, 97-98
 Spontaneous mutation rates, 5, 7, 32-33, 51, 83
 Squirrel monkeys, 85
 Stem cells, in mice, 84, 85
 Subtractive hybridization, 12, 55, 66-67
 "Superfund," 18, 114
 Surveillance, in epidemiologic testing, 14, 103, 104-106, 107

 T-lymphocytes, 74-76
 Technologies, new

- for detecting mutations in humans, 10-19, 55-69
- development of, and research on, 16-19
- and heritable mutations, 3, 10-14, 55-69
- use in research and public policy, 14-16
- Tester mice, 82-83
- Thioguanine resistant (TG^r) cells, 99
- Threonine, 27
- Thymine (T), 23, 24, 27, 64, 66
- Toxic Control Substances Act of 1976 (TSCA), 3, 15, 114, 118
- Transfer RNA (tRNA), 26
- Tryptophan, 27
- Turner's syndrome, 30, 42
- Two-dimensional denaturing gradient gel electrophoresis, 55, 61-64
- Two-dimensional polyacrylamide gel electrophoresis, 56-57
- 2DGGE, see Two-dimensional denaturing gradient gel electrophoresis
- 2-D PAGE, see Two-dimensional polyacrylamide gel electrophoresis
- Tyrosine, 27, 47

- United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 113-114
- U.S. Congress, 4, 15, 16-19, 113; see also U.S. Government
- U.S. Government
 - efforts to protect humans from radiation, 113-114
 - expenditures on mutation research, 15, 18, 117, 121-122
 - regulation by, 15, 17, 113-118
 - role in mutation research, 4, 5, 15, 16-19, 113-118
 - see also** U.S. Congress and *specific Federal agencies*
- Validation of measurement techniques in epidemiologic testing, 104
- Valine, 26, 27, 29
- Viruses, effects on DNA, 23

- White blood cells, somatic mutation studies on, 73, 74-76
- Whole mammal tests, see Specific locus tests; Heritable translocation tests
- Wild-type mice, 82-83
- Wilms' tumor, 7, 31, 109

- Xeroderma pigmentosum, 32
- Yeast, 81, 92, 116

0

LIBRARY
OFFICE OF TECHNOLOGY ASSESSMENT
CONGRESS OF THE UNITED STATES
 WASHINGTON, D.C. 20510